Cytologic Findings and Ancillary Tests Results of Sclerosing Pneumocytoma: Our Institutional Experience
SP is a diagnostic pitfall with 50% initially misdiagnosed as adenocarcinoma. Integrating the clinical/radiologic findings, cytologic features, and performance of immunohistochemistry on cell block are helpful in avoiding misdiagnosis. Molecular testing for recurrent mutations, if present, could be helpful for diagnosis and possible therapy options. However, routinely used molecular testing may not always capture relevant molecular markers for SP.
Authors
- Maria Luisa Policarpio‐Nicolas (ORCID: https://orcid.org/0000-0002-0375-1964)
- Erika Hissong (ORCID: https://orcid.org/0000-0002-2606-6812)
- Elizabeth M. Azzato (ORCID: https://orcid.org/0000-0001-9667-5392)
- Jennifer Brainard (ORCID: https://orcid.org/0000-0002-9773-7580)
- Sydnee Webb
- Rema Rao (ORCID: https://orcid.org/0000-0003-2462-0004)
Institutions
- Cleveland Clinic (US)
- NewYork–Presbyterian Hospital (US)
- Cornell University (US)
- New York Hospital Queens (US)
- Presbyterian Hospital (US)
Publication Details
- Journal
- Diagnostic Cytopathology
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1002/dc.25396
- Citations
- 1
- Primary Topic
- Medical Imaging and Pathology Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.42